4,901 trials
Solid Tumor · Lymphoma, Malignant
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) of S-Warfarin and R-Warfarin — 245; 198; 253; 230 nanograms/milliliter (ng/mL)
Healthy Volunteers
Primary: Number of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) — 0; 2; 0; 4 Participants
Healthy Volunteers
Primary: Urinary and Fecal Excretion of LY2623091 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 60.5; 1.39 percentage of…
Cholestasis
Primary: Period 1: Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of Linerixibat and [14C]-Linerixibat…
Healthy Volunteers
Primary: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2623091 — 61.9; 66.9; 61.8; 64.2 nanograms per milliliter (ng/mL)
Psoriasis
Primary: Change From Baseline in Psoriatic Skin Infiltrate Thickness — 0.89; 0.92; 0.97; 0.93 micrometer (μm) — p=0.9883
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 3; 0 Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab — 6.31; 6.29; 6.50 microgram/milliliter (ug/mL)
Healthy Volunteers
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) for TAK-954 — 4; 3; 0 Participants
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Mantle Cell Lymphoma
Primary: Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) During Phase I — 0; 0; 0; 0 Participants
Breast Cancer · Ovarian Cancer · Colorectal Cancer
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 3; 11; 4; 4 Participants
Solid Tumors
Primary: Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 18; 6; 7 Participants
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Cabotegravir Concentration in Blood Plasma Following IM Administration — 0.0000; 0.2864; 3.2748; 5.1071 Micrograms per milliliter
Melanoma
Primary: Change From Baseline in Mean Number of Adverse Events (Serious and Non Serious Events) — 13.40; 18.40; 23.80; 19.60 Number of adverse events
Type 1 Diabetes Mellitus
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part — 755; 754; 962; 908 Picomoles*hour/Liter…